1Kunsch C,Medford RM.Oxidative stress as a regulator of gene expression in the vasculature[J].Cire Res,1999,85(8):753.
2Erbagel A,Tarakcioglu M,Coskum Y,et al.Mediators of inflammation in children with type 1 diabetes mellitus:cytokines in type 1 diabetic children[J].Clin Biochem,2001,34:645.
3Kaysen GA.The macroinflammatory state in uremia:causes and potential consequences[J].J Am Soc Nephrol,2001,12:1549.
3Taniguchi H, Momiyama Y, Ohmori R, et al. Associations of plasma C-reactive protein levels with the presence and extent of coronary stenosis in patients in patients with stable coronary artery disease. Atherosclerosls ,2005,178 : 173-177.
4Rifai N, Ridker PM. Proposed cardiovascular risk assessment algorithm using high-sensitivity C-reactive protein and lipid screening. Clin Chem,2001,47 :28-30.
5Ayash RS. High-sensitivity C-reactive protein:product claims and the Food and Drug Administration. Clin Chem, 2001,47:1743.
6Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation,2003, 107:363-369.
7Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Meal,2000, 342:836- 843.
8Lindahl B, Toss H, Siegbabn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med ,2000, 343 : 1139-1147.
9Ledue TB, Rifai N. Preanalytic and analytic sources of variations in C-reactive protein measurement: implications for cardiovascular disease risk assessment. Clin Chem,2003, 49 : 1258-1271.
10Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease:application to clinical and public health practice: a statement for health care professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation,2003,107:499-511.
